A., H. B., C. K., P. W., and S. C. W. participated in the last edition of the CHEST Antithrombotic Therapy for VTE Disease Guidelines (AT9). None declared (A. B., J. O., N. S.). Role of sponsors: This study was funded in total by internal funds from the American College of Chest Physicians. Dedication: All of the authors would like to acknowledge the contributions of previous authors of the CHEST Antithrombotic Guidelines. Additional information: The e-Tables and e-Figures can be found in the Supplemental Materials section of the online article. References 1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-494S. 2. Guyatt G, Akl EA, Hirsh J, et al. The vexing problem of guidelines and con ict of interest: a potential solution. Ann Intern Med. 2010;152(11):738-741. 3. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10. 4. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. 5. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407-415. 6. Balshem H, Helfand M, Sch nemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-406. 7. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest. 2006;129(1):174-181. 8. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. 